Articles by National Institute of Allergy and Infectious Diseases

Nanoparticle vaccine targets six flu strains and may need to be taken less than once a year

There is no known cause for this rare immune disorder and no evidence of person-to-person transmissivity

Research needed to propel mucosal vaccine development is a priority

Good safety profile may help MARV vaccine efficiently quell emergency outbreaks

NIAID experts offer perspective on next-generation approaches

The authors note that the epidemiologic pattern of the outbreak of monkeypox resembles that of the early cases of AIDS

The first-in-human, Phase 1 trial will assess the safety and protection of a universal influenza vaccine

Based on Phase 3 trial results, the vaccine was 94.1 percent efficacious in preventing symptomatic COVID-19

Global network to focus on spillover potential

NIH workshop attendees review capabilities, limits of SARS-CoV-2 serology testing

Study enrolling Seattle-based healthy adult volunteers

As of Nov. 12, 36 confirmed cases of EEE had been reported by eight states; 13 of these cases were fatal

Researchers found that the antibodies, which bind to neuraminidase proteins on the surface of influenza viruses, provided broad protection against several different strains of influenza when tested both in vitro and in mice

Researchers plan to develop a simpler, faster, more sensitive test that could be used at the point of care during a single visit to a health care provider

If vaccination rates continue to decline, measles outbreaks may become even more frequent